featured-image

Novartis’s Dr. Tamar Alon and Dr. Evan M.

Beckman talk about the types of research that can drive the company's growth. Novartis employs 5,200 scientists and invests $3.6 billion annually in research, says Dr.



Tamar Alon, Global Head, Early Strategic Partnerships, External Innovation at Novartis, adding that in recent years, several platforms have been launched for collaboration with academic researchers. "Our scientists identify who’s interesting" "We established a network called Novartis Global Scholars, with the participation of 60 institutions from 13 countries, including Israel. Over the last four years, we issued four calls for proposals for special projects in scientific fields of strategic interest to the company, and as a result, we selected twenty academic collaborations in which we invested approximately $1 million each, and they’ve already yielded scientific articles.

" Another program is intended to map world science proactively, aided by Novartis scientists. "Our scientists identify the entities that are most interesting for collaboration, and we offer them a fairly long-term program for product and insight discovery with us. We are looking for global stars, pioneers in their fields, who also think creatively.

" In another program, the Early Impact Fund, the company selects projects and invests 50% of the scientific activity budget. In its first year of activity alone, Novartis has signed five such collaborations. Alon listed the areas where the company is l.

Back to Health Page